{"id":329735,"date":"2026-10-28T10:49:02","date_gmt":"2026-10-28T05:19:02","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=329735"},"modified":"2026-10-28T10:49:02","modified_gmt":"2026-10-28T05:19:02","slug":"largecap-debt-to-equity-below-0-1-stocks-to-watch-multibagger-potential","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/largecap-debt-to-equity-below-0-1-stocks-to-watch-multibagger-potential\/","title":{"rendered":"4 Largecap Debt to Equity Below 0.1 Stocks to Watch for Future Multibagger Potential: Sun Pharma, HAL, Tech Mahindra and Polycab"},"content":{"rendered":"<p style=\"border-left:4px solid #1F4E79;background:#EBF3FB;padding:10px 16px;font-style:italic;\"><em>Sun Pharma Rs 1,751.20. HAL Rs 4,855. Tech Mahindra Rs 1,811.40. Polycab Rs 7,718. Market caps from Rs 1.25 lakh crore to Rs 4.21 lakh crore. Data as of 27 Oct 2026.<\/em><\/p>\n<div style=\"background:#F0F9FF;border-left:4px solid #2E7D32;border-radius:6px;padding:14px 18px;margin:18px 0;\">\n<p style=\"margin:0;color:#1F4E79;font-size:14px;\"><strong>Quick Answer<\/strong><\/p>\n<p style=\"margin:8px 0 0;\">Sun Pharma, HAL, Tech Mahindra and Polycab are the 4 picks in this debt to equity below 0.1 stocks watchlist, with market caps between Rs 1.25 lakh crore and Rs 4.21 lakh crore. Sun Pharma stands out for the fastest profit growth, 35.75% a year since FY22, while HAL offers the biggest five-year price gain at 607.71%. PE ratios run from 31.25 to 42.87, so compare each one with its industry PE before investing. All figures are as of 27 October 2026.<\/p>\n<\/p><\/div>\n<p>Debt to equity below 0.1 stocks to watch for multibagger potential start with a simple filter: size, a clean financial record and earnings that keep growing. Sun Pharma, HAL, Tech Mahindra and Polycab meet that test, with market caps from Rs 1.25 lakh crore to Rs 4.21 lakh crore and Sun Pharma offering the fastest profit growth, 35.75% a year since FY22. Each of these companies has a debt to equity ratio below 0.1, a return on equity of at least 10 per cent and profit growth in FY26 and in the latest quarter, and net profit rose in FY26 and in the latest quarter.<\/p>\n<p>This list covers companies with a debt to equity ratio below 0.1, a return on equity of at least 10 per cent and profit growth in FY26 and in the latest quarter, rising profit in FY26 and the latest quarter, market capitalisation above Rs 1,00,000 crore, and complete, verifiable financials, ranked by market capitalisation. Each company has a market cap above Rs 1 lakh crore. Investors screening debt to equity below 0.1 stocks usually begin with size and balance sheet strength, and this list follows the same logic. All figures are as of 27 October 2026 and are drawn from NSE and BSE data and company filings.<\/p>\n<p style=\"margin-top:24px;\"><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&#038;utm_medium=debt-to-equity-below-stocks\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/largecap-debt-to-equity-below-0-1-stocks-to-watch-multibagger-potential\/#What_Are_Debt_to_Equity_Below_01_Stocks_and_Why_Do_They_Attract_Multibagger_Interest\" title=\"What Are Debt to Equity Below 0.1 Stocks and Why Do They Attract Multibagger Interest?\">What Are Debt to Equity Below 0.1 Stocks and Why Do They Attract Multibagger Interest?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/largecap-debt-to-equity-below-0-1-stocks-to-watch-multibagger-potential\/#Debt_to_Equity_Below_01_Stocks_at_a_Glance_Price_Market_Cap_PE_and_ROE\" title=\"Debt to Equity Below 0.1 Stocks at a Glance: Price, Market Cap, PE and ROE\">Debt to Equity Below 0.1 Stocks at a Glance: Price, Market Cap, PE and ROE<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/largecap-debt-to-equity-below-0-1-stocks-to-watch-multibagger-potential\/#Sun_Pharma_3575_Profit_CAGR_Since_FY22\" title=\"Sun Pharma: 35.75% Profit CAGR Since FY22\">Sun Pharma: 35.75% Profit CAGR Since FY22<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/largecap-debt-to-equity-below-0-1-stocks-to-watch-multibagger-potential\/#HAL_Return_on_Equity_of_2221\" title=\"HAL: Return on Equity of 22.21%\">HAL: Return on Equity of 22.21%<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/largecap-debt-to-equity-below-0-1-stocks-to-watch-multibagger-potential\/#Tech_Mahindra_Debt-to-Equity_of_007\" title=\"Tech Mahindra: Debt-to-Equity of 0.07\">Tech Mahindra: Debt-to-Equity of 0.07<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/largecap-debt-to-equity-below-0-1-stocks-to-watch-multibagger-potential\/#Polycab_3379_Profit_CAGR_Since_FY22\" title=\"Polycab: 33.79% Profit CAGR Since FY22\">Polycab: 33.79% Profit CAGR Since FY22<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/largecap-debt-to-equity-below-0-1-stocks-to-watch-multibagger-potential\/#Debt_to_Equity_Below_01_Stocks_Financial_Comparison_on_Growth_and_Margins\" title=\"Debt to Equity Below 0.1 Stocks: Financial Comparison on Growth and Margins\">Debt to Equity Below 0.1 Stocks: Financial Comparison on Growth and Margins<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/largecap-debt-to-equity-below-0-1-stocks-to-watch-multibagger-potential\/#Institutional_Holding_in_Sun_Pharma_HAL_Tech_Mahindra_and_Polycab\" title=\"Institutional Holding in Sun Pharma, HAL, Tech Mahindra and Polycab\">Institutional Holding in Sun Pharma, HAL, Tech Mahindra and Polycab<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/largecap-debt-to-equity-below-0-1-stocks-to-watch-multibagger-potential\/#Risks_to_Weigh_in_Debt_to_Equity_Below_01_Stocks\" title=\"Risks to Weigh in Debt to Equity Below 0.1 Stocks\">Risks to Weigh in Debt to Equity Below 0.1 Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/largecap-debt-to-equity-below-0-1-stocks-to-watch-multibagger-potential\/#How_to_Choose_Between_Debt_to_Equity_Below_01_Stocks\" title=\"How to Choose Between Debt to Equity Below 0.1 Stocks\">How to Choose Between Debt to Equity Below 0.1 Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/largecap-debt-to-equity-below-0-1-stocks-to-watch-multibagger-potential\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/largecap-debt-to-equity-below-0-1-stocks-to-watch-multibagger-potential\/#Frequently_Asked_Questions_on_Debt_to_Equity_Below_01_Stocks_to_Watch\" title=\"Frequently Asked Questions on Debt to Equity Below 0.1 Stocks to Watch\">Frequently Asked Questions on Debt to Equity Below 0.1 Stocks to Watch<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/largecap-debt-to-equity-below-0-1-stocks-to-watch-multibagger-potential\/#Which_are_the_best_debt_to_equity_below_01_stocks_to_watch_for_multibagger_potential\" title=\"Which are the best debt to equity below 0.1 stocks to watch for multibagger potential?\">Which are the best debt to equity below 0.1 stocks to watch for multibagger potential?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/largecap-debt-to-equity-below-0-1-stocks-to-watch-multibagger-potential\/#Is_Polycab_a_good_stock_for_long-term_investors\" title=\"Is Polycab a good stock for long-term investors?\">Is Polycab a good stock for long-term investors?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/largecap-debt-to-equity-below-0-1-stocks-to-watch-multibagger-potential\/#Can_Sun_Pharma_become_a_multibagger_from_here\" title=\"Can Sun Pharma become a multibagger from here?\">Can Sun Pharma become a multibagger from here?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/largecap-debt-to-equity-below-0-1-stocks-to-watch-multibagger-potential\/#What_is_the_market_cap_of_Sun_Pharma_HAL_Tech_Mahindra_and_Polycab\" title=\"What is the market cap of Sun Pharma, HAL, Tech Mahindra and Polycab?\">What is the market cap of Sun Pharma, HAL, Tech Mahindra and Polycab?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/largecap-debt-to-equity-below-0-1-stocks-to-watch-multibagger-potential\/#What_are_the_risks_of_investing_in_debt_to_equity_below_01_stocks\" title=\"What are the risks of investing in debt to equity below 0.1 stocks?\">What are the risks of investing in debt to equity below 0.1 stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/largecap-debt-to-equity-below-0-1-stocks-to-watch-multibagger-potential\/#Why_is_Tech_Mahindra_trading_at_a_PE_of_3125\" title=\"Why is Tech Mahindra trading at a PE of 31.25?\">Why is Tech Mahindra trading at a PE of 31.25?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/largecap-debt-to-equity-below-0-1-stocks-to-watch-multibagger-potential\/#How_much_do_institutions_hold_in_Sun_Pharma_HAL_Tech_Mahindra_and_Polycab\" title=\"How much do institutions hold in Sun Pharma, HAL, Tech Mahindra and Polycab?\">How much do institutions hold in Sun Pharma, HAL, Tech Mahindra and Polycab?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"What_Are_Debt_to_Equity_Below_01_Stocks_and_Why_Do_They_Attract_Multibagger_Interest\"><\/span><strong>What Are Debt to Equity Below 0.1 Stocks and Why Do They Attract Multibagger Interest?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Debt to equity below 0.1 stocks are shares of large companies that carry almost no borrowing compared with their net worth, which leaves their balance sheets clean and flexible. The four here cover pharmaceuticals, defence aerospace, IT services and cables.<\/p>\n<p>A balance sheet with very little debt means interest costs stay low and more of every rupee earned stays with shareholders. For debt to equity below 0.1 stocks, both FY26 and the latest quarter showed growth. For debt to equity below 0.1 stocks, checking each result against the latest quarter matters more than any single ratio. The next sections explain what stands out in each of debt to equity below 0.1 stocks, using FY26 and latest quarter data. Prices move daily, so recheck the figures for debt to equity below 0.1 stocks before you decide.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Debt_to_Equity_Below_01_Stocks_at_a_Glance_Price_Market_Cap_PE_and_ROE\"><\/span><strong>Debt to Equity Below 0.1 Stocks at a Glance: Price, Market Cap, PE and ROE<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Prices are closing prices as of 27 October 2026. Tech Mahindra has the lowest PE of the group at 31.25, while Polycab posts the highest return on equity at 22.25%.<\/p>\n<table style=\"border-collapse:collapse;width:100%;margin:16px 0;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">Stock<\/th>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">CMP (Rs)<\/th>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">Market Cap (Rs Cr)<\/th>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">PE<\/th>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">Industry PE<\/th>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">ROE<\/th>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">Debt to Equity<\/th>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">52-Week Range (Rs)<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\"><a href=\"https:\/\/univest.in\/stocks\/sunpharma\/sun-pharmaceutical-industries-ltd-share-price-today\">Sun Pharmaceutical Industries<\/a><\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">1,751.20<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">4,20,793<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">34.73<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">36.42<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">13.74%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">0.06<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">1,583.70 to 2,046.90<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\"><a href=\"https:\/\/univest.in\/stocks\/hal\/hindustan-aeronautics-ltd-share-price-today\">Hindustan Aeronautics<\/a><\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">4,855<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">3,31,684<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">35.58<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">48.59<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">22.21%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">0.00<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">3,479.10 to 5,149.90<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\"><a href=\"https:\/\/univest.in\/stocks\/techm\/tech-mahindra-ltd-share-price-today\">Tech Mahindra<\/a><\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">1,811.40<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">1,61,358<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">31.25<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">18.49<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">16.24%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">0.07<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">1,304.10 to 1,854.00<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\"><a href=\"https:\/\/univest.in\/stocks\/polycab\/polycab-india-ltd-share-price-today\">Polycab India<\/a><\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">7,718<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">1,24,541<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">42.87<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">49.96<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">22.25%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">0.02<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">6,663.00 to 10,126.00<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2><span class=\"ez-toc-section\" id=\"Sun_Pharma_3575_Profit_CAGR_Since_FY22\"><\/span><strong>Sun Pharma: 35.75% Profit CAGR Since FY22<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Sun Pharmaceutical Industries is one of India&#8217;s largest drugmakers and sells generic and specialty medicines in India and overseas. It reported FY26 revenue of Rs 61,673.94 crore, up 12.69% year on year, and net profit of Rs 11,564.52 crore, up 5.32%. Net profit has compounded at 35.75% a year since FY22, while revenue has grown 11.62% a year. Operating margin was 31.47% in FY26. The debt-to-equity ratio is 0.06, which keeps interest costs low.<\/p>\n<p>In the June 2026 quarter, revenue rose 11.93% to Rs 16,023.50 crore and net profit grew 26.41% to Rs 2,910.80 crore. The share price has gained 110.81% over five years. Domestic institutions raised their holding from 20.23% in September 2025 to 22.27% in September 2026. The stock trades at a PE of 34.73 against an industry PE of 36.42, below the sector average, with a return on equity of 13.74%.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"HAL_Return_on_Equity_of_2221\"><\/span><strong>HAL: Return on Equity of 22.21%<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Hindustan Aeronautics is India&#8217;s state-owned aerospace company that designs, makes and services fighter jets, helicopters, engines and avionics. It reported FY26 revenue of Rs 36,787.95 crore, up 9.68% year on year, and net profit of Rs 9,115.52 crore, up 8.98%. Net profit has compounded at 15.74% a year since FY22, while revenue has grown 9.48% a year. Operating margin was 40.89% in FY26. The debt-to-equity ratio is 0.00, which keeps interest costs low.<\/p>\n<p>The stock trades at a PE of 35.58 against an industry PE of 48.59, below the sector average, with a return on equity of 22.21%. In the June 2026 quarter, revenue rose 15.26% to Rs 6,415.41 crore and net profit grew 14.88% to Rs 1,589.66 crore. The share price has gained 607.71% over five years. Domestic institutions raised their holding from 8.71% in September 2025 to 12.56% in September 2026.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Tech_Mahindra_Debt-to-Equity_of_007\"><\/span><strong>Tech Mahindra: Debt-to-Equity of 0.07<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Tech Mahindra, part of the Mahindra Group, provides IT and business services to telecom and other global clients. It reported FY26 revenue of Rs 56,847.30 crore, up 5.58% year on year, and net profit of Rs 4,805.50 crore, up 12.99%. Revenue has compounded at 5.57% a year since FY22. Operating margin was 15.47% in FY26. The debt-to-equity ratio is 0.07, which keeps interest costs low.<\/p>\n<p>In the September 2026 quarter, revenue rose 15.23% to Rs 16,172.80 crore and net profit grew 33.95% to Rs 1,609.70 crore. The share price is up 16.96% over the past year. Domestic institutions raised their holding from 32.13% in June 2025 to 36.92% in June 2026. The stock trades at a PE of 31.25 against an industry PE of 18.49, with a return on equity of 16.24%. The dividend yield is 3.09%.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Polycab_3379_Profit_CAGR_Since_FY22\"><\/span><strong>Polycab: 33.79% Profit CAGR Since FY22<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Polycab India is a leading maker of wires and cables in India, with a growing fast-moving electrical goods business. It reported FY26 revenue of Rs 29,120.04 crore, up 28.76% year on year, and net profit of Rs 2,708.43 crore, up 32.41%. Net profit has compounded at 33.79% a year since FY22, while revenue has grown 24.06% a year. Operating margin was 14.69% in FY26. The debt-to-equity ratio is 0.02, which keeps interest costs low.<\/p>\n<p>The stock trades at a PE of 42.87 against an industry PE of 49.96, below the sector average, with a return on equity of 22.25%. In the June 2026 quarter, revenue rose 38.90% to Rs 8,314.65 crore and net profit grew 32.84% to Rs 796.65 crore. The share price has gained 230.55% over five years. Foreign investors raised their holding from 11.44% in June 2025 to 19.00% in June 2026.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Debt_to_Equity_Below_01_Stocks_Financial_Comparison_on_Growth_and_Margins\"><\/span><strong>Debt to Equity Below 0.1 Stocks: Financial Comparison on Growth and Margins<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The table compares scale and growth across these debt to equity below 0.1 stocks. Latest quarter means the most recent reported quarter for each company, and only metrics that are positive for every company are shown.<\/p>\n<table style=\"border-collapse:collapse;width:100%;margin:16px 0;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">Stock<\/th>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">Net Profit (Rs Cr)<\/th>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">Revenue Growth (YoY)<\/th>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">4-Year Revenue CAGR<\/th>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">Latest Quarter Revenue Growth<\/th>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">Operating Margin (Latest Quarter)<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">Sun Pharma<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">61,673.94<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">11,564.52<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">12.69%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">11.62%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">11.93%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">32.52%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">HAL<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">36,787.95<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">9,115.52<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">9.68%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">9.48%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">15.26%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">44.22%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">Tech Mahindra<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">56,847.30<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">4,805.50<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">5.58%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">5.57%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">15.23%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">17.74%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">Polycab<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">29,120.04<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">2,708.43<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">28.76%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">24.06%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">38.90%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">15.12%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p style=\"margin-top:24px;\"><a href=\"https:\/\/univest.in\/screeners\"><strong>Check the Univest Screener for live data on these debt to equity below 0.1 stocks<\/strong><\/a><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Institutional_Holding_in_Sun_Pharma_HAL_Tech_Mahindra_and_Polycab\"><\/span><strong>Institutional Holding in Sun Pharma, HAL, Tech Mahindra and Polycab<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Institutional holding shows who is backing these debt to equity below 0.1 stocks alongside the promoter. The table uses the latest reported quarter for each. Tech Mahindra has the deepest institutional backing, with FII and DII together holding 55.58% as of June 2026. Domestic institutions increased their holding over the past year in Sun Pharma (from 20.23% to 22.27%), HAL (from 8.71% to 12.56%) and Tech Mahindra (from 32.13% to 36.92%).<\/p>\n<table style=\"border-collapse:collapse;width:100%;margin:16px 0;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">Stock<\/th>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">Promoter<\/th>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">FII<\/th>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">DII<\/th>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">Public<\/th>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">Quarter<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">Sun Pharma<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">52.68%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">14.36%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">22.27%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">10.70%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">September 2026<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">HAL<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">71.64%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">9.42%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">12.56%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">6.38%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">September 2026<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">Tech Mahindra<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">34.97%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">18.66%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">36.92%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">9.45%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">June 2026<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">Polycab<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">61.46%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">19.00%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">7.62%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">11.92%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">June 2026<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2><span class=\"ez-toc-section\" id=\"Risks_to_Weigh_in_Debt_to_Equity_Below_01_Stocks\"><\/span><strong>Risks to Weigh in Debt to Equity Below 0.1 Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Being careful with debt to equity below 0.1 stocks means looking at what can slow the story as well as what can speed it up. Four points matter most:<\/p>\n<ul>\n<li>Past growth may not repeat.<\/li>\n<li>Share prices can move sharply in either direction.<\/li>\n<li><strong>Valuation:<\/strong> Tech Mahindra trades at a PE of 31.25 against an industry PE of 18.49, so earnings need to keep growing to support the price.<\/li>\n<li><strong>Concentration:<\/strong> Holding all 4 names puts the allocation in one sector, so size each position to match your risk appetite.<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"How_to_Choose_Between_Debt_to_Equity_Below_01_Stocks\"><\/span><strong>How to Choose Between Debt to Equity Below 0.1 Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Picking from debt to equity below 0.1 stocks comes down to four checks, applied in order.<\/p>\n<ol>\n<li>Check balance sheet strength first, and prefer a debt-to-equity ratio below 1 for non-financial companies.<\/li>\n<li>Compare each PE with the industry PE (18.49 to 49.96) and ask whether the growth rate justifies any gap.<\/li>\n<li>Track net profit growth, the operating margin and the return on equity in every quarterly result.<\/li>\n<li>Stagger entries across quarters and review institutional holding every reporting season.<\/li>\n<\/ol>\n<p style=\"margin-top:24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&#038;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track Sun Pharma, HAL, Tech Mahindra and Polycab live prices.<\/em><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among debt to equity below 0.1 stocks, Sun Pharma stands out for the fastest profit growth, 35.75% a year since FY22, HAL for the biggest five-year price gain at 607.71%, Tech Mahindra for the strongest latest-quarter profit growth at 33.95% and Polycab for the highest return on equity at 22.25%. Which one suits a portfolio depends on how much valuation risk it can carry, so staggering entries and reviewing each quarterly result is a sound habit. Investors comparing debt to equity below 0.1 stocks should rank them on growth, financial strength and the price paid, and anyone who wants personalised guidance can consult a SEBI-registered advisor before acting.<\/p>\n<div style=\"background:#CC0000;border-radius:8px;padding:16px 20px;margin:24px 0;\">\n<p style=\"color:#FFFFFF;font-size:13px;line-height:1.7;margin:0;\"><strong style=\"color:#FFFFFF;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/p><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions_on_Debt_to_Equity_Below_01_Stocks_to_Watch\"><\/span><strong>Frequently Asked Questions on Debt to Equity Below 0.1 Stocks to Watch<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Which_are_the_best_debt_to_equity_below_01_stocks_to_watch_for_multibagger_potential\"><\/span><strong>Which are the best debt to equity below 0.1 stocks to watch for multibagger potential?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Sun Pharma, HAL, Tech Mahindra and Polycab are the 4 names this list highlights, with market caps of Rs 4,20,793 crore, Rs 3,31,684 crore, Rs 1,61,358 crore and Rs 1,24,541 crore respectively. Sun Pharma is notable for the fastest profit growth, 35.75% a year since FY22. HAL stands out for the biggest five-year price gain at 607.71%. Tech Mahindra offers the strongest latest-quarter profit growth at 33.95%. Polycab brings the highest return on equity at 22.25%. These are watchlist names for debt to equity below 0.1 stocks, not recommendations, so match each one to your own risk profile and time horizon.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_Polycab_a_good_stock_for_long-term_investors\"><\/span><strong>Is Polycab a good stock for long-term investors?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Polycab has a return on equity of 22.25%, a PE of 42.87 against an industry PE of 49.96 and a market cap of Rs 1,24,541 crore. Net profit has compounded at 33.79% a year since FY22, and FY26 revenue rose 28.76% while June 2026 quarter net profit grew 32.84%. Long-term returns in debt to equity below 0.1 stocks depend on earnings growth and the price paid at entry, so staggering purchases and consulting a SEBI-registered advisor is sensible.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Can_Sun_Pharma_become_a_multibagger_from_here\"><\/span><strong>Can Sun Pharma become a multibagger from here?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Sun Pharma has already gained 110.81% in five years, so another multi-fold move would need sustained earnings growth. A multibagger outcome in debt to equity below 0.1 stocks requires earnings to keep growing faster than the market for several years. Net profit has compounded at 35.75% a year since FY22, and FY26 revenue rose 12.69%. At a PE of 34.73 against an industry PE of 36.42, valuation should be checked against that growth before investing.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_market_cap_of_Sun_Pharma_HAL_Tech_Mahindra_and_Polycab\"><\/span><strong>What is the market cap of Sun Pharma, HAL, Tech Mahindra and Polycab?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> As of 27 October 2026, Sun Pharma has a market cap of Rs 4,20,793 crore, HAL has a market cap of Rs 3,31,684 crore, Tech Mahindra has a market cap of Rs 1,61,358 crore and Polycab has a market cap of Rs 1,24,541 crore. All of them qualify as largecaps. Market cap changes daily with the share price, so check the latest figure on the Univest Screener or on NSE before taking a decision on debt to equity below 0.1 stocks.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_are_the_risks_of_investing_in_debt_to_equity_below_01_stocks\"><\/span><strong>What are the risks of investing in debt to equity below 0.1 stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The main risks are market swings, slower growth than expected and valuations that already reflect good news. Companies with strong balance sheets and steady earnings handle these better. Tech Mahindra trades at a PE of 31.25 against an industry PE of 18.49, so earnings growth needs to hold up.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Why_is_Tech_Mahindra_trading_at_a_PE_of_3125\"><\/span><strong>Why is Tech Mahindra trading at a PE of 31.25?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Tech Mahindra&#8217;s PE of 31.25 compares with an industry PE of 18.49. The market is paying a premium for a return on equity of 16.24% and latest-quarter profit growth of 33.95%, which also means the stock is more sensitive if growth slows. Investors in debt to equity below 0.1 stocks who are comfortable with higher valuation risk may prefer to stagger purchases instead of investing in one go.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_much_do_institutions_hold_in_Sun_Pharma_HAL_Tech_Mahindra_and_Polycab\"><\/span><strong>How much do institutions hold in Sun Pharma, HAL, Tech Mahindra and Polycab?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> As of the latest reported quarter, FII and DII together hold 36.63% of Sun Pharma (14.36% and 22.27%), 21.98% of HAL (9.42% and 12.56%), 55.58% of Tech Mahindra (18.66% and 36.92%) and 26.62% of Polycab (19.00% and 7.62%). Rising institutional holding is a useful signal in debt to equity below 0.1 stocks, though it should be read with earnings trends rather than on its own.<\/p>\n<p><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"Which are the best debt to equity below 0.1 stocks to watch for multibagger potential?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Sun Pharma, HAL, Tech Mahindra and Polycab are the 4 names this list highlights, with market caps of Rs 4,20,793 crore, Rs 3,31,684 crore, Rs 1,61,358 crore and Rs 1,24,541 crore respectively. Sun Pharma is notable for the fastest profit growth, 35.75% a year since FY22. HAL stands out for the biggest five-year price gain at 607.71%. Tech Mahindra offers the strongest latest-quarter profit growth at 33.95%. Polycab brings the highest return on equity at 22.25%. These are watchlist names for debt to equity below 0.1 stocks, not recommendations, so match each one to your own risk profile and time horizon.\"}},{\"@type\":\"Question\",\"name\":\"Is Polycab a good stock for long-term investors?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Polycab has a return on equity of 22.25%, a PE of 42.87 against an industry PE of 49.96 and a market cap of Rs 1,24,541 crore. Net profit has compounded at 33.79% a year since FY22, and FY26 revenue rose 28.76% while June 2026 quarter net profit grew 32.84%. Long-term returns in debt to equity below 0.1 stocks depend on earnings growth and the price paid at entry, so staggering purchases and consulting a SEBI-registered advisor is sensible.\"}},{\"@type\":\"Question\",\"name\":\"Can Sun Pharma become a multibagger from here?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Sun Pharma has already gained 110.81% in five years, so another multi-fold move would need sustained earnings growth. A multibagger outcome in debt to equity below 0.1 stocks requires earnings to keep growing faster than the market for several years. Net profit has compounded at 35.75% a year since FY22, and FY26 revenue rose 12.69%. At a PE of 34.73 against an industry PE of 36.42, valuation should be checked against that growth before investing.\"}},{\"@type\":\"Question\",\"name\":\"What is the market cap of Sun Pharma, HAL, Tech Mahindra and Polycab?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"As of 27 October 2026, Sun Pharma has a market cap of Rs 4,20,793 crore, HAL has a market cap of Rs 3,31,684 crore, Tech Mahindra has a market cap of Rs 1,61,358 crore and Polycab has a market cap of Rs 1,24,541 crore. All of them qualify as largecaps. Market cap changes daily with the share price, so check the latest figure on the Univest Screener or on NSE before taking a decision on debt to equity below 0.1 stocks.\"}},{\"@type\":\"Question\",\"name\":\"What are the risks of investing in debt to equity below 0.1 stocks?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The main risks are market swings, slower growth than expected and valuations that already reflect good news. Companies with strong balance sheets and steady earnings handle these better. Tech Mahindra trades at a PE of 31.25 against an industry PE of 18.49, so earnings growth needs to hold up.\"}},{\"@type\":\"Question\",\"name\":\"Why is Tech Mahindra trading at a PE of 31.25?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Tech Mahindra's PE of 31.25 compares with an industry PE of 18.49. The market is paying a premium for a return on equity of 16.24% and latest-quarter profit growth of 33.95%, which also means the stock is more sensitive if growth slows. Investors in debt to equity below 0.1 stocks who are comfortable with higher valuation risk may prefer to stagger purchases instead of investing in one go.\"}},{\"@type\":\"Question\",\"name\":\"How much do institutions hold in Sun Pharma, HAL, Tech Mahindra and Polycab?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"As of the latest reported quarter, FII and DII together hold 36.63% of Sun Pharma (14.36% and 22.27%), 21.98% of HAL (9.42% and 12.56%), 55.58% of Tech Mahindra (18.66% and 36.92%) and 26.62% of Polycab (19.00% and 7.62%). Rising institutional holding is a useful signal in debt to equity below 0.1 stocks, though it should be read with earnings trends rather than on its own.\"}}]}<\/script><\/p>\n","protected":false},"excerpt":{"rendered":"<p>4 largecap debt to equity below 0.1 stocks compared on market cap, PE, ROE, growth and institutional holding: Sun Pharma, HAL, Tech Mahindra and Polycab.<\/p>\n","protected":false},"author":33,"featured_media":329734,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[845],"tags":[16991,16990],"class_list":["post-329735","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-best-stocks","tag-debt-to-equity-below-0-1-sector","tag-debt-to-equity-below-0-1-stocks"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["329734"],"rank_math_title":["Debt to Equity Below 0.1 Stocks 2026: Sun Pharma, HAL"],"rank_math_description":["Debt to equity below 0.1 stocks to watch for multibagger potential: Sun Pharma, HAL, Tech Mahindra and Polycab. Compare market cap, PE, ROE and growth before you invest."],"rank_math_focus_keyword":["debt to equity below 0.1 stocks"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/10\/4-largecap-debt-to-equity-below-0-1-stocks-to-watch-for-future-multibagger.webp","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/329735","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/33"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=329735"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/329735\/revisions"}],"predecessor-version":[{"id":329736,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/329735\/revisions\/329736"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/329734"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=329735"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=329735"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=329735"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}